Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

Open access

Published version of a preprint

Abstract

PURPOSE: To evaluate the effects of BRAF inhibition on the tumor microenvironment in patients with metastatic melanoma. EXPERIMENTAL DESIGN: Thirty-five biopsies were collected from 16 patients with metastatic melanoma pretreatment (day 0) and at 10 to 14 days after initiation of treatment with either BRAF inhibitor alone (vemurafenib) or BRAF + MEK inhibition (dabrafenib + trametinib) and were also taken at time of progression. Biopsies were analyzed for melanoma antigens, T-cell markers, and immunomodulatory cytokines. RESULTS: Treatment with either BRAF inhibitor alone or BRAF + MEK inhibitor was associated with an increased expression of melanoma antigens and an increase in CD8+ T-cell infiltrate. This was also associated with a decrease in immunosuppressive cytokines [interleukin (IL)-6 and IL-8] and an increase in markers of T-cell cytotoxicity. Interestingly, expression of exhaustion markers TIM-3 and PD1 and the immunosuppressive ligand PDL1 was increased on treatment. A decrease in melanoma antigen expression and CD8 T-cell infiltrate was noted at time of progression on BRAF inhibitor alone and was reversed with combined BRAF and MEK inhibition. CONCLUSIONS: Together, these data suggest that treatment with BRAF inhibition enhances melanoma antigen expression and facilitates T-cell cytotoxicity and a more favorable tumor microenvironment, providing support for potential synergy of BRAF-targeted therapy and immunotherapy. Interestingly, markers of T-cell exhaustion and the immunosuppressive ligand PDL1 are also increased with BRAF inhibition, further implying that immune checkpoint blockade may be critical in augmenting responses to BRAF-targeted therapy in patients with melanoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-1630

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 944

Metadata

Authors
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., Peng, W., Sullivan, R. J., Lawrence, D. P., Hodi, F. S., Overwijk, W. W., Lizée, G., Murphy, G. F., Hwu, P., Flaherty, K. T., Fisher, D. E., & Wargo, J. A.
Affiliations
  • Brigham and Women's Hospital (US)
  • Authors' Affiliations: Divisions of 1Surgical Oncology, 2Medical Oncology, 3Dermatopathology, and 4Dermatology, Massachusetts General Hospital; 5Department of Medical Oncology, Dana-Farber Cancer Institute; 6Division of Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts; and 7Department of Melanoma Medical Oncology, Center for Cancer Immunology Research, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Corresponding author
Wargo, Jennifer A.
Venue
Clinical Cancer Research
Published
2013-03-01
Volume
19
Issue
5
Pages
1225-1231
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2114903025
Cited by
944
References
23
Citations by year
2026: 24 · 2025: 29 · 2024: 35 · 2023: 66 · 2022: 69 · 2021: 77 · 2020: 88 · 2019: 79 · 2018: 87 · 2017: 97 · 2016: 79 · 2015: 85 · 2014: 87 · 2013: 41
FWCI
43.63
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute (U54CA163125, K08CA160692, P30CA016672, P01CA163222)
  • National Institute of General Medical Sciences (T32GM007753)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR043369)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords
metastatic melanoma, BRAF inhibition, vemurafenib, dabrafenib, trametinib, tumor microenvironment, melanoma antigens, CD8+ T cell infiltration, T cell exhaustion, TIM-3, PD-1, PD-L1, interleukin-6, interleukin-8, immune checkpoint blockade, immunotherapy synergy
MeSH terms
Vemurafenib, Fluorescent Antibody Technique, Humans, Imidazoles, Indoles, Melanoma, Neoplasm Staging, Oximes, Prognosis, Pyridones, Pyrimidinones, RNA, Messenger, Sulfonamides, Biomarkers, Tumor, Blotting, Western, Apoptosis, Reverse Transcriptase Polymerase Chain Reaction, Cell Line, Tumor, MAP Kinase Kinase 1, Proto-Oncogene Proteins B-raf, Cell Proliferation, Melanoma-Specific Antigens, Tumor Microenvironment, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-1630
The paper
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., Peng, W., Sullivan, R. J., Lawrence, D. P., Hodi, F. S., Overwijk, W. W., Lizée, G., Murphy, G. F., Hwu, P., Flaherty, K. T., . . . Wargo, J. A. (2013). BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-1630

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.